Orders by weight:
An inducible cre deleter under the control of the vascular endothelial cadherin (Cdh5(PAC)) promoter
Cre recombination is inducible via administration of tamoxifen
Useful for study of angiogenesis, atherosclerosis and neovascularization
Non-induced Cdh5(PAC)-CreERT2 mice demonstrate no Cre recombinase activity, while tamoxifen-induced Cdh5(PAC)-CreERT2 mice demonstrate high levels of recombinase-mediated gene deletion in vascular endothelial cells (95%+).
Taconic cannot accept orders by weight for this model. Please note that shipments may contain animals with a larger weight variation.
Origin: The Cdh5(PAC)-CreERT2 Mouse was developed in the laboratory of Ralf Adams at the London Research Institute. The model was generated by microinjecting a transgene containing a genomic Cdh5(PAC) promoter fragment fused to a CreERT2 cDNA into C57BL/6 zygotes. Founder lines were backcrossed to C57BL/6 for at least five generations. Taconic received embryos from CRT in 2013.
Source: Sponsor: Cancer Research Technology
Availability: Limited quantities of breeders are available for purchase after execution of a license.
Ordering Note: Animals ordered at 4 weeks of age require rapid genotyping and a $40.00 per mouse charge will be added.
Sörensen I, Adams RH, Gossler A. (2009) DLL1-mediated Notch activation regulates endothelial identity in mouse fetal arteries. Blood. 113(22):5680-8